Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential

Share:
Related ALNY
25 Stocks Which Rallied Four Days, Then Sold Off Yesterday
William Blair Sees An End To Sarepta's Regulatory Saga, Upgrades And Lifts Price Target To $88

In a report published Friday, Deutsche Bank analyst Alethia Young initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and $40.00 price target.

In the report, Young noted, “Alnylam is an early stage company that uses a technology called RNA interference that occurs naturally in the body to silence problematic genes in diseases that were previously deemed un-druggable. We believe Alnylam has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales. We initiate with a Buy rating and a $40 target price.”

Alnylam Pharmaceuticals closed on Thursday at $28.06.

Latest Ratings for ALNY

DateFirmActionFromTo
Aug 2016JP MorganMaintainsOverweight
Aug 2016JefferiesMaintainsBuy
Aug 2016Morgan StanleyInitiates Coverage onOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!